<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008513</url>
  </required_header>
  <id_info>
    <org_study_id>AFF006A</org_study_id>
    <secondary_id>2012-005280-27</secondary_id>
    <nct_id>NCT02008513</nct_id>
  </id_info>
  <brief_title>Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006</brief_title>
  <official_title>A Randomized, Controlled, Parallel Group, Double-blind, Multi-centre, Phase IIb Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in the AFFITOPE® AD02 Phase II Study AFF006.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiris AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiris AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02
      vaccinations in patients with Alzheimer's disease. Patients, who have already participated in
      AFF006 will be involved in 27 study sites in Europe. Duration of patient's participation in
      the clinical trial is 19 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study AFF006A was early terminated by the sponsor based on the results of study AFF006.
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Measures of Primary Safety and Tolerability Endpoints</measure>
    <time_frame>19 months</time_frame>
    <description>Withdrawal criteria
Number of Adverse events (AEs)
Number of any serious adverse events (SAE)
Alzheimer's Disease Assessment Scale - Cognition (ADAScog)
Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory (ADCS-ADL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Measures of Secondary Efficacy Endpoints</measure>
    <time_frame>19 months</time_frame>
    <description>Clinical Dementia Rating Sum of Boxes (CDR-sb)
Free and Cued Selective Reminding Test (FCSRT)
Standard neuropsychological test battery (CogState)
Mini-Mental State Examination (MMSE)
Investigator's global evaluation scale (IGE)
CDR [global aspects]
Neuropsychiatric Inventory (NPI) [behavior]
quality of life (QOL) -AD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AFFITOPE® AD02</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients having participated in AFF006+having received 6 investigational medicinal
             product (IMP) injections+having completed all visits

          -  Written informed consent

          -  Availability of a partner/caregiver

          -  Female patients of childbearing potential are eligible if they use a medically
             accepted contraceptive method.

          -  Scheduled elective hospitalization for diagnostic work-up is allowed for inclusion
             into the clinical trial.

        Exclusion Criteria:

          -  Pregnant women.

          -  Sexually active women of childbearing potential who are not using a medically accepted
             birth control method and unreliable contraception in male subjects.

          -  Participation in the active treatment phase of another clinical trial except AFF006
             within 3 months before Visit 0.

          -  History of questionable compliance to visit schedule; patients not expected to
             complete the clinical trial.

          -  Presence or history of allergy to components of the vaccine, if considered relevant by
             the investigator.

          -  Contraindication for MRI imaging

          -  Presence and/or history of immunodeficiency (e.g., HIV infection).

          -  Prior and/or current treatment with experimental immunotherapeutics including
             Intravenous immunoglobulin (IVIG), AD antibody therapy and/or vaccines for AD except
             AD02.

          -  Prior and/or current treatment with immunosuppressive drugs.

          -  Treatment with benzodiazepines and/or nootropics administered at high doses and/or as
             newly started treatment.

          -  Treatment with anticholinergic drugs including Parkinson treatments, antidepressants
             (tricyclics), neuroleptics with anticholinergic properties, certain bladder relaxants,
             anticholinergic drugs for use in lung diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Dubois, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre des Maladies Cognitives et Comportementales, Federation des maladies du systeme nerveux, Hoptial de la Salpetriere, Pavillon Paul Castaignes (Sous-sol), 47-83 Bd de l'Hopital, 75651 Paris Cedex 13</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Hall Gedächtnisambulanz</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LNK Wagner-Jauregg, Dept. of geriatrics</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Doppler Klinik, Univ. Klinik f. Neurologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUW Klin. Pharmakologie und Klinik für Neurologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUW, Klin.Abt.f. Biolog. Psychiatrie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMZ-Ost, Psychiatric Dep.</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinčki Bolnički Centar Rijeka, Klinika za Psihijatriju</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opća bolnica Varaždin, Klinika za Neurologiju</name>
      <address>
        <city>Varaždin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;BONIFARM&quot; Poliklinika za kliničku farmakologiju i toksikologiju</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psihijatrijska Bolnica Vrapče</name>
      <address>
        <city>Zagreb</city>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Thomayer Hospital</name>
      <address>
        <city>Praha</city>
        <zip>14950</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol, Clinic of Neurology</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Mémoire de Ressources et de Recherche, Service de Neurologie</name>
      <address>
        <city>Montpellier Cedex</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Site Hôtel Dieu</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La Grave</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin, Klinik u. Hochschulambulanz f. Psychiatrie u. Psychotherapie</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arzneimittelforschung Leipzig GmbH, Studienzentrum</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für Seelische Gesundheit, Abt. Gerontopsychiatrie</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik f. Psychiatrie u. Psychotherapie der TU München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum PD Dr. Steinwachs</name>
      <address>
        <city>Nürnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroPoint GmbH</name>
      <address>
        <city>Ulm/Donau</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPAMED, s.r.o.</name>
      <address>
        <city>Kosice</city>
        <zip>04017</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AFFITOPE® AD02</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Brain Disease</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Mental Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 19, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

